Vijayakrishna Gadi, MD, PhD, discusses factors to consider in the first- and second-line management of HER2+ mBC with particular emphasis on treatment selection, safety, and sequencing.
Back
The Evolving Paradigm in the Treatment of HER2 Positive Metastatic Breast Cancer
Vijayakrishna Gadi, MD, PhD, provides an overview of recent advancements in the treatment of HER2+ metastatic breast cancer with special consideration for challenges in the management of patients with CNS metastases.
The Evolving Paradigm in the Treatment of HER2 Positive Metastatic Breast Cancer
Episodes
All
All
An expert oncologist reviews key considerations in selecting and sequencing treatment appropriately in patients with HER2+ breast cancer and CNS metastases, including challenges associated with treating leptomeningeal disease.
EP. 3: Role of Multidisciplinary Team in the Management of Patients with HER2+ BC and CNS Metastases
Highlighting the importance of a multidisciplinary approach to care in HER2+ mBC, Vijayakrishna Gadi, MD, PhD, describes the value of effective consultation with neurooncologists and radiation oncologists for CNS metastases.
A leader in breast medical oncology reflects on key clinical trial updates presented at the 2022 ASCO Annual Meeting, and their implications for clinical practice.
Advertisement
Advertisement
Trending on OncLive
1
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Longer-Term Data Continue to Support Earlier Integration of CAR T-Cell Therapy in R/R Myeloma
4
Trastuzumab Rezetecan Elicits High ORR in HER2-High and HER2-Low Salivary Gland Carcinoma
5